Cenra Inc

Cenra Inc operates with a debt-to-equity ratio of 0.39 and a current ratio of 1.4, indicating moderate liquidity and a balanced capital structure. The company's price-to-book ratio of 0.67 suggests that the market values the company at a discount to its book value, while the price-to-earnings ratio of 16.8 reflects a moderate valuation relative to earnings. In terms of profitability, Cenra Inc reports a return on equity (ROE) of 3.96% and a return on assets (ROA) of 2.41%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that the company is generating relatively modest returns on its equity and asset base. The company's revenue is derived from a mix of pharmaceuticals, medical equipment, animal medicines, and personal hygiene products. However, the financial snapshot does not provide a breakdown of revenue by segment or geography, making it difficult to assess the concentration of risk in any particular area. Looking ahead, the outlook for Cenra Inc is not explicitly detailed in the provided data. The company's operating cash flow of 740.6 million TWD and free cash flow of 283.9 million TWD suggest a positive cash flow position, but the absence of specific growth projections or revenue deltas limits the ability to assess future performance. The risk assessment for Cenra Inc indicates a medium liquidity risk and a low dilution risk. However, the company's net cash position is negative after subtracting total debt, which could pose a challenge in maintaining liquidity under adverse conditions. There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The absence of specific events or transcripts means that the company's recent activities and strategic direction are not clearly defined.